Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 FormulationsCompleted
NCT02908269Phase 4Updated Mar 29, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
United States
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy ChildrenCompleted
NCT02915302Phase 4Updated Mar 29, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
United States, United Kingdom
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 FormulationsCompleted
NCT03617523Phase 4Updated Mar 29, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
United States
Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)Completed
NCT02332590Phase 3Updated Mar 28, 2022
Sponsor: Sanofi
Rheumatoid Arthritis
United States, Chile, Czechia, Germany, Hungary +10 more
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic AgentsTerminated
NCT03434119Phase 3Updated Mar 28, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
United States
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCATerminated
NCT03600805Phase 3Updated Mar 28, 2022
Sponsor: Sanofi
Giant Cell Arteritis
United States, Argentina, Australia, Belgium, Canada +16 more
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome InhibitorUnknown
NCT05298683Phase 2Updated Mar 28, 2022
Sponsor: Hellenic Society of Hematology
Multiple Myeloma · Renal Impairment · Neoplasms, Plasma Cell · Neoplasms by Histologic Type
Greece
Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South KoreaCompleted
NCT01900444Phase 3Updated Mar 28, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis
South Korea
Evaluation of Dupilumab in Children With Uncontrolled AsthmaCompleted
NCT02948959Phase 3Updated Mar 28, 2022
Sponsor: Sanofi
Asthma
United States, Argentina, Australia, Brazil, Canada +13 more
Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)Completed
NCT01146652Phase 3Updated Mar 28, 2022
Sponsor: Sanofi
Rheumatoid Arthritis
United States, Argentina, Australia, Austria, Belarus +35 more
Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin GlargineCompleted
NCT03211858Phase 3Updated Mar 28, 2022
Sponsor: Sanofi
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
United States, Finland, Germany, Hungary, Japan +2 more
A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and ToddlersCompleted
NCT01049035Phase 2Updated Mar 28, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningitis · Meningococcal Infection
United States
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe DiseaseCompleted
NCT01410890Phase 4Updated Mar 28, 2022
Sponsor: Genzyme, a Sanofi Company
Pompe Disease · Glycogen Storage Disease Type II (GSD II)
United States, Bulgaria, India, Russia, Ukraine +1 more
Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy SubjectsCompleted
NCT02492165Phase 3Updated Mar 28, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis
Vietnam
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes MellitusCompleted
NCT02688933Phase 4Updated Mar 28, 2022
Sponsor: Sanofi
Type 1 Diabetes Mellitus
United States, Puerto Rico
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without InhibitorsCompleted
NCT03417245Phase 3Updated Mar 28, 2022
Sponsor: Genzyme, a Sanofi Company
Hemophilia A · Hemophilia B
United States, Australia, China, Denmark, France +14 more
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile InfectionTerminated
NCT01887912Phase 3Updated Mar 28, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Clostridium Difficile Infection
United States, Australia, Brazil, Canada, Colombia +21 more
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)Completed
NCT02134028Phase 3Updated Mar 28, 2022
Sponsor: Sanofi
Asthma
United States, Argentina, Australia, Belgium, Brazil +22 more
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)Completed
NCT02476006Phase 3Updated Mar 28, 2022
Sponsor: Sanofi
Hypercholesterolemia
Austria, Belgium, Canada, Czechia, Denmark +11 more
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With InhibitorsCompleted
NCT03417102Phase 3Updated Mar 28, 2022
Sponsor: Genzyme, a Sanofi Company
Hemophilia A · Hemophilia B
United States, Australia, Canada, China, France +12 more
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)Completed
NCT03093480Phase 4Updated Mar 28, 2022
Sponsor: Bioverativ, a Sanofi company
Hemophilia A With Inhibitors
United States, Belgium, Bulgaria, Canada, France +5 more
Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving LemtradaCompleted
NCT03784898Phase 4Updated Mar 28, 2022
Sponsor: Genzyme, a Sanofi Company
Multiple Sclerosis
United States
Regulatory Post-Marketing Surveillance Study for TETRAXIM™Completed
NCT01437423Phase 4Updated Mar 28, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Diphtheria · Tetanus · Pertussis · Poliomyelitis
South Korea
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 YearsCompleted
NCT03077438Phase 3Updated Mar 28, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningitis · Meningococcal Meningitis · Meningococcal Infections
United States, Puerto Rico
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)Completed
NCT02878603Phase 3Updated Mar 28, 2022
Sponsor: Sanofi
Acquired Thrombotic Thrombocytopenic Purpura
United States, Austria, Belgium, Canada, Czechia +8 more

Previous page Next page